Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The company’s leadership team represents a group of drug development executives with unparalleled success in the industry. Central to Oncoceutics’ scientific and technology base is a focus on drug discovery that engages natural potent tumor suppressor pathways. The first lead compound that came out of this program is ONC201, a small molecule that possesses significant anti-tumor activity in a number of different types of human cancer through a unique mechanism of action. The compelling preclinical efficacy and safety of ONC201 along with its favorable chemical properties offer a high potential for safe and meaningful therapeutic benefit to cancer patients in numerous clinical settings. Clinical lead indications for ONC201 are being evaluated in a series of clinical trials that are in various stages of initiation at leading cancer centers around the world.

Senior Management


Wolfgang Oster
Chief Executive Officer Wolfgang Oster, M.D., Ph.D. is board certified in internal medicine, hematology/oncology, and served as Adjunct Professor at Brown University. For 25 years he has worked in the Life Science Industry as an executive, investor and entrepreneur. Dr. Oster was responsible for leading 9 Marketing Authorization Applications to successful global approvals. As an investor, several of his companies accomplished market introductions or major development inflection points leading to a total of 2 major trade sales and 5 IPOs.
Lee Schalop
Chief Business Officer Lee Schalop, M.D. is the company’s chief business officer, a role he has held since graduating with a doctor of medicine degree from the Albert Einstein College of Medicine in 2008. Prior to attending medical school, Dr. Schalop spent more than 19 years in the financial industry at a number of major Wall Street firms, including Morgan Stanley, J.P. Morgan, Credit Suisse and Banc of Banc of America Securities.
Martin Stogniew
Chief Development Officer Martin Stogniew, Ph.D. brings 32 years of senior executive experience in the pharmaceutical industry and has served as an independent member of the Board of Directors for Provid Pharmaceuticals. Dr. Stogniew has made significant contributions resulting in FDA approval of 8 New Drug Applications, issuance of 27 US patents, and closure of 4 major M&A deals totaling ~3 billion dollars.
Joshua Allen
Director of Development Joshua Allen, Ph.D. is the co-inventor of ONC201 who discovered the drug in the lab and possesses a deep technical knowledge of the product and field. Dr. Allen is an experienced cancer researcher with a proven capacity to design, execute and manage translational scientific studies that have resulted in clinical and commercial engagement in oncology.

Contact Us


Full Name(require)
Email(require)
Number(require)
Message(require)

News and Updates


Oncoceutics’ Second Generation Program for ONC201 Receives NIH SBIR Grant For Collaboration with Provid Pharmaceuticals and Pennsylvania State University

Hummelstown, PA (August 8, 2014) – Oncoceutics, Inc., a biotechnology company focused on developing innovative oncology treatments addressing major unmet medical needs to advance cancer care, announced that an NIH SBIR grant (1R43CA177002) has been awarded by the National Cancer Institute to develop second-generation analogs for its lead product, ONC201. The grant will fund research […]

Oncoceutics Receives ONC201 Research Grant From Musella Foundation For Brain Tumor Research & Information

Hummelstown, PA (June 18, 2014) – Oncoceutics, Inc., a biotechnology company focused on developing innovative oncology treatments addressing major unmet medical needs to advance cancer care, announced that the Musella Foundation For Brain Tumor Research & Information, Inc, has awarded Oncoceutics a research grant to study ONC201 in glioblastoma multiforme (GBM), the most aggressive form […]

Penn State Researcher Receives Conquer Cancer Foundation’s Young Investigator Award for Project on Oncoceutics’ Lead Compound ONC201

Hummelstown, PA (June 9, 2014) – Oncoceutics, Inc., a biotechnology company focused on developing innovative oncology treatments addressing major unmet medical needs to advance cancer care, announces that Pennsylvania State University researcher Mala Talekar, MD, received a Young Investigator Award at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting from The Conquer Cancer […]

Oncoceutics Announces Response to Publication in Angewandte Chemie International Edition Regarding Oncoceutics’ Lead Compound ONC201

Hummelstown, PA (May 28, 2014) – Oncoceutics, Inc., a biotechnology company focused on developing innovative oncology treatments addressing major unmet medical needs to advance cancer care, announces a response to the publication in Angewandte Chemie International Edition entitled “Pharmacophore Reassignment for Induction of the Immunosurveillance Cytokine TRAIL” and related news reports that discussed Oncoceutics’ lead […]